Safety of the reduced fixed dose of mycophenolate mofetil confirmed via therapeutic drug monitoring in de novo kidney transplant recipients
The current reduced fixed-dose MMF strategy can help achieve the therapeutic target of MPA exposure in tacrolimus- treated Korean KTRs during the early posttransplant period.
Authors
- Dong Il Won (ORCID: https://orcid.org/0000-0002-1983-2515)
- Deokbi Hwang (ORCID: https://orcid.org/0000-0003-0050-6434)
- Seung Huh (ORCID: https://orcid.org/0000-0002-0275-4960)
- Chan‐Duck Kim (ORCID: https://orcid.org/0000-0002-4648-0324)
- Woo‐Sung Yun (ORCID: https://orcid.org/0000-0001-8956-8310)
- Hee‐Yeon Jung (ORCID: https://orcid.org/0000-0003-0232-7202)
- Jeong‐Hoon Lim (ORCID: https://orcid.org/0000-0001-5517-9886)
- Hyung-Kee Kim (ORCID: https://orcid.org/0000-0002-4436-7424)
- Ji‐Young Choi (ORCID: https://orcid.org/0000-0002-9774-3665)
- Eun Sang Yoo (ORCID: https://orcid.org/0000-0002-7442-6886)
- Jang‐Hee Cho (ORCID: https://orcid.org/0000-0002-7031-5214)
- Yong-Lim Kim (ORCID: https://orcid.org/0000-0002-1344-3455)
- Sun-Hee Park (ORCID: https://orcid.org/0000-0002-0953-3343)
- Yu Jin Seo
Institutions
- Kyungpook National University Hospital (KR)
- Kyungpook National University (KR)
Publication Details
- Journal
- Kidney Research and Clinical Practice
- Published
- 2024-10-24
- DOI
- https://doi.org/10.23876/j.krcp.23.274
- Citations
- 4
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.03
Funders
- Ministry of Health and Welfare
- Korea Health Industry Development Institute